Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant TACE/Ablation Plus Sintilimab + Ipilimumab N01 ± Lenvatinib for Resectable HCC at Intermediate-High Recurrence Risk
ChiCTR2600120784Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sintilimab, ipilimumab and lenvatinib in hepatocellular carcinoma (HCC) (4 arms), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoint: 1-year recurrence-free survival rate. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
sintilimabipilimumablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2600120784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600120784.